Showing results (1-10 of 82) with videos related to

Sort By:
Pageof 9
Clinical Lymphoma, Myeloma & Leukemia|May 29, 2018
Optimal Management of Histone Deacetylase Inhibitor-Related Adverse Events in Patients With Multiple Myeloma: A Focus on PanobinostatJamie D Cavenagh, Rakesh Popat
Expert Opinion on Biological Therapy|July 31, 2020
Antibody-drug conjugates for multiple myelomaAnnabel McMillan, Dana Warcel, Rakesh Popat
Leukemia & Lymphoma|October 6, 2007
Use of bortezomib as induction therapy prior to stem cell transplantation in frontline treatment of multiple myeloma: impact on stem cell harvesting and engraftmentHeather Oakervee, Rakesh Popat, Jamie D Cavenagh
Expert Opinion on Pharmacotherapy|June 30, 2006
Bortezomib for multiple myelomaRakesh Popat, Simon Joel, Heather Oakervee, et al.
American Journal of Hematology|October 6, 2022
Antibody drug conjugates for the treatment of multiple myelomaSarah Leong, Ho Pui Jeff Lam, Zoe Kirkham, et al.
Frontiers in Oncology|December 25, 2023
Patient-reported experiences during and following treatment with belantamab mafodotin for relapsed/refractory multiple myeloma in the DREAMM-2 studyAnna Cardellino, Julia R Correll, Mona Martin, et al.
Clinical Hematology International|October 29, 2024
Management of multiple myeloma presenting as malignant spinal cord compression during pregnancy: a case reportKhushnuma Mullanfiroze, Charlotte Jones, David Williams, et al.
British Journal of Haematology|March 29, 2008
Bortezomib, doxorubicin and dexamethasone (PAD) front-line treatment of multiple myeloma: updated results after long-term follow-upRakesh Popat, Heather E Oakervee, Simon Hallam, et al.
British Journal of Haematology|October 22, 2016
Whole body magnetic resonance imaging in newly diagnosed multiple myeloma: early changes in lesional signal fat fraction predict disease responseArash Latifoltojar, Margaret Hall-Craggs, Neil Rabin, et al.
Advances in Therapy|September 25, 2021
DREAMM-2: Indirect Comparisons of Belantamab Mafodotin vs. Selinexor + Dexamethasone and Standard of Care Treatments in Relapsed/Refractory Multiple MyelomaThibaud Prawitz, Rakesh Popat, Attaya Suvannasankha, et al.
Pageof 9